Will Johnson & Johnson's New Alzheimer's Partnership Unlock New Potential Treatments?
Johnson & Johnson recently signed a deal with Evotec to go back to the drawing board and develop new treatments for Alzheimer’s disease. What does this deal mean for Pfizer, Eli Lilly, Merck, and AstraZeneca, which have also been pursuing the same goal?
Alzheimer's Disease Could Become the Next Frontier in Pharmaceutical Research
Despite being the sixth-leading cause of death in the United States, Alzheimer's disease is still a large unknown. Here's a rundown of what risk factors contribute to the disease, what drugs are available to treat it now, and where research is currently headed.
Don't Put All Your Money on One-Trick Ponies
Diversification is not as simple as choosing stocks in different sectors. We use Lorillard, PepsiCo, and Pfizer to highlight the importance of internal diversification.